DailyIQ
|
Sector:HealthcareAll sectors
Last updated 3 minutes ago

LLY·Eli Lilly and Company

$.
-. (-.%)
After Hours
High
$1,226.60
Open
$1,210.31
Market Cap
1118.66B
52W High
$1,249.45
Low
$1,178.32
P. Close
$1,188.25
P/E
44.26
52W Low
$623.78
Fwd P/E
26.52
DailyIQ Est.
$1301.09
Technical Score (1D)
82
BUY
News Sentiment
77
BULLISH
Kestra Advisory Services LLC just disclosed a $112.88 million stake in Eli Lilly, signaling fresh institutional confidence that could tighten liquidity and influence upcoming shareholder votes. This new stake arrives amid a wave of analyst upgrades, with Bank of America raising its price target to $1,334 from $1,251 and maintaining a Buy rating, reflecting optimism about Lilly’s earnings trajectory and product pipeline. The concurrent lift in price targets from multiple houses—Morgan Stanley, Wolfe Research, Cantor Fitzgerald, Berenberg Bank, and Sanford C. Bernstein—reinforces a consensus bullish stance that could buoy short‑term momentum. These developments suggest that the market is pricing in a near‑term upside as Lilly’s pipeline, particularly its diabetes and oncology assets, is expected to deliver incremental revenue in the coming quarters. The positive sentiment is likely to support trading activity over the next 1–10 days, as investors look to capitalize on the upgraded valuations. Traders should watch for the next earnings release, where guidance on drug sales and regulatory milestones will either confirm or temper the optimistic outlook. Additionally, any updates on product approvals—especially for Lilly’s key oncology candidates—could serve as a catalyst for further price movement. The Zacks Investment Ideas feature, which highlighted LLY among top biotech picks, underscores sector momentum driven by AI and semiconductor gains, suggesting that broader biotech enthusiasm may amplify Lilly’s upside. Finally, keep an eye on any subsequent analyst revisions or corporate actions that could alter the current consensus, as the market remains sensitive to pipeline progress and shareholder dynamics.
Earnings Summary
Eli Lilly and Company (LLY) is a global pharmaceutical firm specializing in human medicines across diabetes, oncology, and immunological disorders, with flagship products such as Mounjaro, Trulicity, and Verzenio. In its latest earnings cycle, LLY posted Q4 2025 EPS of $7.54 versus an estimate of $6.7372 and revenue of $19.292 billion versus an estimate of $18.138 billion, while Q1 2026 EPS surged to $8.55 against an estimate of $6.7921 and revenue rose to $19.799 billion; both quarters reflected EPS beats and revenue growth of 2.6% year‑over‑year, continuing a streak of earnings beats in all quarters except Q1 2025, which saw a modest EPS miss. Historically, LLY has maintained a consistent upward trajectory in both revenue and EPS, with a pattern of beating analyst estimates and expanding its product portfolio, particularly in the GLP‑1 space. Recent news underscores this momentum: a surge in GLP‑1 uptake to 11% of U.S. adults, the launch of Medicare Bridge programs expanding access to Zepbound and Foundayo, and Canada’s approval of Mounjaro for pediatric type 2 diabetes, all of which are expected to lift domestic sales and broaden revenue streams. Investors should watch for the Q2 2026 earnings release to confirm the continued earnings beat, monitor the rollout pace of the Medicare Bridge program and Canadian pediatric Mounjaro sales, and track progress on Lilly’s AI‑driven discovery platform and upcoming oncology approvals, as these developments will be key to sustaining the company’s growth trajectory.

EPS

EstBeatMiss
$2.54$4.27$6.01$7.74$9.47Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$8.67 - -
Q1'26$6.79$8.55+25.9%
Q4'25$6.74$7.54+11.9%
Q3'25$5.89$7.02+19.2%
Q2'25$5.59$6.31+12.9%
Q1'25$3.54$3.34-5.7%

Revenue

EstBeatMiss
$11.6B$14.1B$16.6B$19.1B$21.7BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$20.5B - -
Q1'26$17.8B$19.8B+11.1%
Q4'25$18.1B$19.3B+6.4%
Q3'25 - $17.6B -
Q2'25 - $15.6B -
Q1'25 - $12.7B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

LLY Stock Snapshot

LLY is currently trading at $1188.14, giving Eli Lilly and Company a market cap of 1118.66B and a P/E ratio of 44.3. Today's range spans $1178.32–$1226.60, with shares opening at $1210.31 and moving down $0.11 (0.0%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 77/100.

Over the past year LLY has traded between $623.78 and $1249.45 - the current price is +90.5% off the 52-week low and -4.9% from the high. 39 analysts cover the stock with a Buy consensus and a mean 12-month target of $1240.46 (range $850.00–$1500.00), implying upside of +4.4%.

Eli Lilly and Company (LLY) has earned its mega-cap status in Healthcare - and the current data backs it up. Technical score 82/100 (BUY), sentiment 77/100 (bullish), price $1188.14 (near 52-week highs). (P/E: 44.3) The 52-week window from $623.78 to $1249.45 establishes the range, and the current bullish reading says this stock isn't testing support - it's testing what the next leg of the trend looks like.

For portfolio managers constructing Healthcare exposure, a mega-cap with a BUY signal and bullish news backdrop represents the kind of conviction-generating setup that justifies moving from benchmark weight to overweight. The 82/100 technical score at $1188.14 (near 52-week highs) provides the entry discipline; the 1118.66B market cap provides the exit liquidity — a combination most position-sizing frameworks actively seek.